Search Results - "Muszbek, Noemi"

Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma by Muszbek, Noemi, Remak, Edit, Xin, Qian, McNamara, Linda, Jones, Trefor

“…This study assessed the cost-utility of mogamulizumab, a novel monoclonal antibody, versus established clinical management (ECM) in UK patients in previously…”
Get full text

The Cost-Effectiveness of Pixantrone for Third-/Fourth-Line Treatment of Aggressive Non-Hodgkin’s Lymphoma by Muszbek, Noemi, MSc, Kadambi, Ananth, PhD, Lanitis, Tereza, MSc, Hatswell, Anthony J., MSc, Patel, Dilip, BSc, Wang, Lixia, PhD, Singer, Jack W., MD, Pettengell, Ruth, PhD

“…Abstract Purpose Aggressive non-Hodgkin’s lymphoma (aNHL) is associated with poor long-term survival after relapse, and treatment is limited by a lack of…”
Get full text

Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence by Kaló, Zoltán, Muszbek, Noémi, Bodrogi, József, Bidló, Judit

“…Therapeutic reference pricing is one of the potential cost containment methods for pharmaceuticals. The most critical question of reference pricing is how to…”
Get full text

Overview of Parametric Survival Analysis for Health-Economic Applications by Ishak, K. Jack, Kreif, Noemi, Benedict, Agnes, Muszbek, Noemi

“…Health economic models rely on data from trials to project the risk of events (e.g., death) over time beyond the span of the available data. Parametric…”
Get full text

Overall survival in the UK in mycosis fungoides or S ´ ezary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care by Neil Hawkins, Noemi Muszbek, Rachel Evans, Linda McNamara, Trefor Jones

“…Aim: Due to extensive treatment switching in the MAVORIC trial, lack of UK regulatory licence for the comparator, overall survival (OS) with mogamulizumab was…”
Get full text

Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care by Hawkins, Neil, Muszbek, Noemi, Evans, Rachel, McNamara, Linda, Jones, Trefor

“…Aim: Due to extensive treatment switching in the MAVORIC trial, lack of UK regulatory licence for the comparator, overall survival (OS) with mogamulizumab was…”
Get full text

Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome by Hawkins, Neil, Muszbek, Noemi, Evans, Rachel, Dequen-O'Byrne, Pascale, Jones, Trefor, McNamara, Linda

“…Relative overall survival (OS) estimates reported in the MAVORIC trial are potentially confounded by a high proportion of patients randomized to vorinostat…”
Get full text

Cost–utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma by Muszbek, Noemi, Remak, Edit, Evans, Rachel, Brennan, Victoria K, Colaone, Fabien, Shergill, Suki, Mullan, Damian, Ross, Paul J

“…The study assessed the cost-utility of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in UK patients with…”
Get full text

Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC) by Muszbek, Noemi, Evans, Rachel, Remak, Edit, Brennan, Victoria K, Colaone, Fabien, Shergill, Suki, Ross, Paul, Mullan, Damian

“…While essential for cost-effectiveness analyses, there are no current resource use and cost data available for advanced hepatocellular carcinoma (HCC) and…”
Get more information

Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors by Muszbek, Noemi, Proudfoot, Clare, Fournier, Marie, Chen, Chieh-I, Kuznik, Andreas, Kiss, Zsofia, Gal, Peter, Michaud, Kaleb

“…Despite a substantial number of treatment options in rheumatoid arthritis (RA) following tumor necrosis factor inhibitor (TNFi) inadequate response or…”
Get full text

Economic evaluation of sorafenib in unresectable hepatocellular carcinoma by Carr, Brian I., Carroll, Stuart, Muszbek, Noemi, Gondek, Kathleen

“…Background and Aim:  A double‐blind, randomized phase III trial of sorafenib in advanced hepatocellular carcinoma demonstrated that sorafenib significantly…”
Get full text

Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs by Muszbek, Noemi, Proudfoot, Clare, Fournier, Marie, Chen, Chieh-I, Kuznik, Andreas, Kiss, Zsofia, Gal, Peter, Michaud, Kaleb

“…Introduction Assess the cost-effectiveness (US healthcare payer perspective) of sarilumab subcutaneous (SC) 200 mg + methotrexate versus conventional synthetic…”
Get full text

Comparative healthcare-associated costs of meticillin-resistant Staphylococcus aureus bacteraemic infective endocarditis treated with either daptomycin or vancomycin by Browne, Chantelle, Muszbek, Noemi, Chapman, Ruth, Marsh, Kevin, Gould, Ian M, Seaton, R. Andrew, Allen, Mike

“…Highlights • Vancomycin resistance has caused greater interest in the use of daptomycin. • Daptomycin lowers clinical failure rates compared with vancomycin in…”
Get full text

Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia-infective endocarditis treated with either daptomycin or vancomycin by Browne, Chantelle, Muszbek, Noemi, Chapman, Ruth, Marsh, Kevin, Gould, Ian M., Seaton, R. Andrew, Allen, Mike

“…•Vancomycin resistance has caused greater interest in the use of daptomycin.•Daptomycin lowers clinical failure rates compared with vancomycin in patients with…”
Get full text

Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective by Borse, Rebekah H., Brown, Chloe, Muszbek, Noemi, Chaudhary, Mohammad Ashraf, Kachroo, Sumesh

“…Introduction Golimumab is a tumor necrosis factor-α (TNF-α) inhibitor for treatment of patients with severe, active ankylosing spondylitis. This study…”
Get full text

Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada by Muszbek, Noemi, Shah, Sonalee, Carroll, Stuart, McDonald, Heather, Dale, Peter, Maroun, Jean, Knox, Jennifer

“…ABSTRACT Background: A randomized phase III trial of sorafenib vs. placebo in hepatocellular carcinoma (HCC) demonstrated that sorafenib significantly…”
Get full text

Modelling survival in hepatocellular carcinoma by Muszbek, Noemi, Kreif, Noemi, Valderrama, Adriana, Benedict, Agnes, Ishak, Jack, Ross, Dr. Paul

“…Abstract Objectives: To identify the pattern of the risk of death over long-term in unresectable hepatocellular carcinoma by determining the appropriate…”
Get full text

Using daptomycin in hospitalised patients with cSSTI caused by Staphylococcus aureus has an impact on costs by Muszbek, Noemi, Chapman, Ruth, Browne, Chantelle, Marsh, Kevin, Gould, Ian M, Brown, Ruth E, Balp, Maria-Magdelana, Allen, Mike

“…The aim was to assess the cost impact of daptomycin compared to vancomycin treatment in patients hospitalised for complicated skin and soft-tissue infection…”
Get more information

Public health value of fixed-dose combinations in hypertension by Ruilope, Luis M, Burnier, Michel, Muszbek, Noemi, Brown, Ruth E, Keskinaslan, Abdulkadir, Ferber, Philippe, Harms, Günter

“…It is well documented that reducing blood pressure (BP) in hypertensive individuals reduces the risk of cardiovascular (CV) events. Despite this, many patients…”
Get more information

Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis by Palmer, Andrew J., Valentine, William J., Ray, Joshua A., Roze, Stephane, Muszbek, Noemi

“…To perform a health economic analysis on treatment with irbesartan in patients with type 2 diabetes and hypertension. A Markov model was adapted to the…”
Get full text